Aug. 13, 2025 — Registration is now open for the RSNA 111th Scientific Assembly and Annual Meeting, the world’s leading annual radiology forum.

The meeting will take place Nov. 30-Dec. 4, in Chicago at McCormick Place.

Aug. 13, 2025 — A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest Complete radiation shielding system, demonstrating its superior ability to protect all personnel in the catheterization lab from scatter radiation. The findings show that while other next-generation systems offer protection for the primary operator and assistant, the EggNest™ Complete system provides significant protection for the entire interventional team.

Aug. 11, 2025 — Elucid announced that United Healthcare has updated its cardiac imaging guidelines to align with recent recommendations from radiology benefit manager EviCore. United Healthcare’s new guidelines now include coronary computed tomography angiography (CTA) plaque quantification, specifically encompassing Elucid’s PlaqueIQ technology. The coverage will apply to all United Healthcare plans effective Oct. 1, 2025.

Aug. 07, 2025 —- New research by European cybersecurity company Modat revealed more than 1.2 million internet-connected healthcare devices and systems are exposed and vulnerable to exploitation endangering patient data. The number one finding in the study showed there are more than 174,000 exposed systems in the United States (most results are across Europe, the USA, and the MENA). 

Aug. 4, 2025 — Living with cardiovascular disease often takes a serious emotional toll — and with stress known to worsen heart health, there’s growing interest in low-risk, innovative ways to help patients cope. New research from UCLA Health suggests that virtual reality (VR) may offer a promising tool to ease psychological stress and support heart health. 

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care setting, recently announced the publication of a study showing that the company’s Vivio System used with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) in primary care practices accurately identified previously undiagnosed HF patients who could benefit from further treatment to improve or manage their condition. The article appears in the current issue of JACC: Advances.

Aug. 5, 2025 — HeartBeam, a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S. and international patents, with additional applications pending.

Aug. 4, 2025 — Corcym announced that its Perceval Plus sutureless aortic heart valve was used in a first-ever robotic aortic valve replacement, through a tiny incision in the neck of a patient. The procedure was performed by Marijan Koprivanac, MD, surgeon at Cleveland Clinic's Heart, Vascular & Thoracic Institute. 

Aug. 4, 2025 — A new peer-reviewed study in the American Journal of Preventive Cardiology shows Hello Heart’s digital heart health program is associated with significant blood pressure reductions among women with hypertension, including those in perimenopause and postmenopause — life stages where cardiovascular risk sharply increases but is often under-addressed in routine care.

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines for cardioendocrine diseases, recently announced that the first patient has been enrolled in its Phase 2b TYDAL-TIMI 78 study evaluating MAR001 in adults with elevated levels of triglycerides (TG) and remnant cholesterol (RC) at increased risk of atherosclerotic cardiovascular disease (ASCVD). MAR001 is a monoclonal antibody delivered by subcutaneous injection that is designed to block the activity of ANGPTL4, a protein that is highly expressed in adipose tissue.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now